Previous 10 | Next 10 |
source: Investopedia I've recently been trading a lot of stocks associated with the COVID-19 pandemic, as well as gold stocks, as their volatility make for great opportunities to generate some serious profits quickly, based upon the rapid movement of the share price. While these moveme...
Preface: We believe most pre-commercial biotechs do not trade like traditional stocks, being largely event-driven. Hence, our approach focuses heavily on the science and much less so on the financials. Of course, metrics such as cash burn and debt are important and do inform our decision mak...
VANCOUVER, Washington, April 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
VANCOUVER, Washington, April 09, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CytoDyn's ( CYDY ) high-energy CEO Nadir Pourhassan [NP] has been in his element in the fast-paced news cycle attendant upon all things COVID-19. Today, as I write on 4/7/20, he has responded to both a Charles Payne Fox Business interview along with another in his series of regular Proactiv...
VANCOUVER, Washington and WINSTON-SALEM, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeut...
NEW YORK, April 07, 2020 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting companies which recently presented at its NEXT SUPER STOCK livestream investor conference series which are making news headlines this week. Wall Street Report...
April 7, 2020 Palm Beach, FL – April 7, 2020 – As the global health crisis quickly spreads in the United States, officials face the daunting task of treating patients in person and monitoring their progress. With quarantines increasing throughout the world, healthca...
CytoDyn ( OTCQB:CYDY ) is collaborating with the U.K.’s Department of Health to provide emergency access to leronlimab, an investigational medicine for COVID-19. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...
VANCOUVER, Washington, April 07, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...